Xeris Pharmaceuticals | XERS - Assets


Xeris Pharmaceuticals reported $383.53M in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
Celltrion KRW 21.08T 530.63B Sep/2025
Cspc Pharmaceutical CNY 46.7B 695.56M Dec/2025
Deva Holding AS TRY 12.93B 1.83B Sep/2023
Dianthus Therapeutics USD 530.92M 46.52M Dec/2025
Divis Laboratories Ltd INR 181.51B 12.19B Sep/2025
Eli Lilly USD 112.48B 2.46B Dec/2025
Kangmei Pharma CNY 13.68B 38.19M Sep/2025
Knight Therapeutics CAD 1.05B 2.28M Dec/2025
Laboratorios Farma EUR 799.88M 99.95M Dec/2023
Malin Corporation EUR 198.5M 70.1M Dec/2024
Medical Developments International AUD 63.57M 2.83M Dec/2025
Nektar Therapeutics USD 280.41M 20.94M Dec/2025
Neuren Pharmaceuticals AUD 342.86M 11.61M Dec/2025
Organigram Holdings CAD 530.67M 31.54M Dec/2025
Ovoca Bio EUR 1.66M 9.75M Jun/2025
Pacira USD 1.26B 32.66M Dec/2025
Perrigo USD 8.54B 1.55B Dec/2025
Pharma Mar EUR 395.08M 53.42M Dec/2025
Qiagen NV USD 6.3B 257.54M Dec/2025
Sartorius EUR 9.61B 413.4M Sep/2025
Sino Biopharmaceutical CNY 74.89B 9.49B Jun/2025
Supernus Pharmaceuticals USD 1.45B 32.89M Dec/2025
Tilray USD 2.1B 15.95M Sep/2025
Zealand Pharma A/S 15.95B 848.45M Dec/2025
Zz Pientze Pharmaceu CNY 17.48B 1.23B Sep/2025